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Received 22 April 2009; received in revised form 24 May 2009; accepted 26 May 2009Abstract Transplantation of human embryonic stem cell-derived cardiomyocytes (hESC-CM) has been shown to improve the
function of the rodent heart 1 month after myocardial infarction (MI). However, the mechanistic basis and optimal delivery
strategies are unclear. We investigated the influence of the number of injected cells, resulting graft size, and possible
paracrine mechanisms in this process. MI was induced in NOD-SCID mice (n=84) followed by injection of enriched hESC-CM at
different dosages, hESC-non-CM derivatives, culture medium, or no injection. Cardiac function was monitored for 12 weeks
with 9.4 T MRI (n=70). Grafts were identified by epifluorescence of a transgenic GFP marker and characterized by
immunofluorescence. Vascularity and paracrine effects were investigated immunohistochemically. Transplantation of
differentiated hESCs improved short, mid-, and long-term cardiac performance and survival, although only cardiomyocytes
formed grafts. A mid-term (4 weeks) cardiomyocyte-specific enhancement was associated with elevated vascular density
around the graft and attenuated compensatory remodeling. However, increasing the number of hESC-CM for injection did not
enhance heart function further. Moreover, we observed that small graft size was associated with a better functional
outcome. HESC-CM increased myocardial vascularization and enhanced heart function in mice after MI, but larger graft size
was associated with reduced functional improvement. Future studies should focus on advanced delivery strategies and
mechanisms of action rather than increasing graft size.
© 2009 Elsevier B.V. All rights reserved.⁎ Corresponding author. Fax: +31 71526 8289.
E-mail address: c.l.mummery@lumc.nl (C.L. Mummery).
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Cardiomyocyte-based cell therapy has recently emerged as
a potential approach to heart repair for disease associated
with loss of vital cardiomyocytes. This includes myocardial
infarction (MI) and subsequent heart failure. Human.
Figure 1 HESC-derived grafts in the infarcted mouse heart
consist predominantly of cardiomyocytes: (a, b) Most (≥90%)
hESC-derived cells 12 weeks after myocardial infarction and cell
injection express α-actinin (cardiomyocyte); (c, d) some hESC-
CM also stain positive for Ki67; (e, f) a minority of the hESC-
derived cells express cytokeratin 8 (CK8) (endoderm). Green,
GFP; blue, nuclei. Scale bars: 20 μm.
107HESC-CM; vascularity post-MI and graft sizeembryonic stem cells (hESCs) are among the most promising
candidate sources of cardiomyocytes because of their
capacity to proliferate indefinitely and undergo directed
differentiation into bona fide cardiomyocytes (Kehat et al.,
2001; Laflamme et al., 2007; Mummery et al., 2003) in vitro
with an immature phenotype most likely to survive trans-
plantation. Induced pluripotent stem cells (iPS cells) derived
from human skin fibroblasts (Yu et al., 2007; Takahashi et al.,
2007) may in the future become a comparable alternative.
Whatever the cardiomyocyte source, however, issues of
correct integration and coupling with the host myocardium
and cell fate in vivo remain to be addressed and optimal cell
dosages and delivery methods have not yet been established.
Recently, studies investigating hESC-based regeneration
have been carried out in rats and mice (Laflamme et al.,
2007; Caspi et al., 2007; Leor et al., 2007; van Laake et al.,
2007). Although the number and composition of injected
cells, the timing of injection after MI, the method of immune
suppression, and the functional readouts have varied, all
studies reported significant mid-term (4 weeks post-MI)
improvements in cardiac function resulting from transplan-
tation of hESC-derived cell populations containing cardio-
myocytes (hESC-CM) compared to vehicle injection or
transplantation of noncardiomyocyte derivatives. However,
when the follow-up time was extended to 12 weeks, the
advantage of hESC-CM over hESC-non-CM was no longer
present (van Laake et al., 2007). In view of the unknown
optimal dose of cells for transplantation, the small graft size
observed in all studies may explain the lack of sustained
improvement in cardiac function despite cardiomyocyte
survival even at 3 months post-MI and transplantation
(Rubart and Field, 2007). However, in our recent pilot
study we found that increasing the numbers of injected
hESC-CM did not lead to further enhancement of cardiac
function (van Laake et al., 2008). Another possibility is that
hESC-CM exert paracrine effects which may be beneficial to
cardiac performance, as has been shown with mesenchymal
stem cells (Gnecchi et al., 2005).
Here, we explored these hypotheses in more detail by
comparing the effects of injection of hESC-CM at different
dosages with hESC-non-CM derivatives, culture medium, or
no injection at all after experimental MI in immunodeficient
NOD-SCID mice.Results
Previously we showed that transplantation of mixed popula-
tions of differentiated hESCs containing 20–25% cardiomyo-
cytes, compared to differentiated hESCs nearly devoid of
cardiomyocytes, improved cardiac function 4 weeks after MI
in NOD-SCID mice (van Laake et al., 2007). However, this
advantage of transplanting cardiomyocytes over other hESC-
derived cells was lost in the long term (12 weeks) (van Laake
et al., 2007) even though only cardiomyocytes had formed
substantial grafts (Figs. 1a and b and Supplementary Fig. 1).
Some cardiomyocytes were still in the cell cycle (Figs. 1c and
d) but the majority were postmitotic. Cardiomyocytes
composed 80–95% of the grafts; the remaining cells
expressed the endoderm-marker cytokeratin 8 (troma-1)
(Figs. 1e and f). Only rarely (b1%) were cells positive for CD31
or smooth muscle actin (not shown). Cell survival was 1.46±1.02% of all injected cells 4 weeks after transplantation,
corresponding to 6.8±4.6% of injected cardiomyocytes).
To test the hypothesis that the small graft size relative to
the total infarct area might be the reason for a lack of long-
term cardiomyocyte-specific functional improvement, we
injected three times as many cardiomyocyte-enriched
differentiated HESCs directly after coronary artery ligation.
This resulted in a significant increase in total graft size 12
weeks after MI and transplantation, as described (van Laake
et al., 2008) (mean semiquantitative score 7.17±0.44
arbitrary units (AU) after injection of 3×106 cells vs 3.75±
0.72 AU after injection of 1×106 cells; P=0.010). This again
resulted in preservation of cardiac function compared to the
control group receiving hESC-non-CM at 4 weeks, but not at
12 weeks (Fig. 2).
To exclude a possible negative effect of the injection
needle manipulation itself, we also included groups of
infarcted mice that received injection with vehicle (culture
medium) or no injection at all. Longitudinal follow-up by
MRI demonstrated a positive effect of injection of either
hESC-CM or hESC-non-CM compared to injection of culture
Figure 2 Cardiac function after myocardial infarction is improved by transplantation of differentiated hESCs: Longitudinal follow-
up by serial MRI measurements of mice after myocardial infarction and injection of 1×106 or 3×106 million hESC-CM, 1×106 hESC-non-
CM, medium, or no injection. Days: days postoperatively. EDV, end diastolic volume; ESV, end systolic volume; EF, ejection fraction; SV,
stroke volume. ⁎ Pb 0.05 for 1×106 CM, 3×106 CM, and 1×106 non-CM vs no injection, # Pb0.05 for 1×106 CM vs medium and no
injection, † Pb 0.05 for 1×106 CM, and 3×106 CM vs no injection, ‡ Pb 0.05 for 3×106 CM vs non-CM.
Figure 3 Survival of mice after myocardial infarction: Survival
until 12 weeks (end point) of mice after myocardial infarction
and injection of 1×106 or 3×106 million hESC-CM, 1×106 hESC-
non-CM, medium, or no injection. Week: weeks postoperatively.
108 L.W. van Laake et al.medium or no treatment, as evidenced by improved end
diastolic volume (EDV), end systolic volume (ESV), and
ejection fraction (EF) (Fig. 2; reference data from non-
infarctedmice in Supplementary Fig. 2). While at 4 weeks the
benefit from hESC-CM was greater than that of hESC-non-CM,
at 12 weeks both cell types had preserved cardiac function
equally well compared to the controls without cell injection
(Fig. 2). In addition, the mice that received injection with
culture medium performed better than the noninjected
controls (Fig. 2). Therefore, intramyocardial injection itself
did not impair cardiac function to any significant extent; in
fact it may have been beneficial. Furthermore, injection of
either cell type or medium increased long-term survival of
the mice compared to noninjected controls (Fig. 3).
Since increased mean graft size did not improve heart
function per experimental group of mice, we investigated
whether there was a relationship between graft size and
cardiac function in mice within one group. Mice were
retrospectively divided in two subgroups with graft size
below or above the median of their own group (i.e., 1×106
hESC-CM or 3×106 hESC-CM, as the hESC-non-CM only rarely
produced a very small graft). The average “small” graft size
in the 3×106 hESC-CM group (6.14±0.40 AU) was comparable
to the average “large” graft size in the 1×106 hESC-CM group
(5.57±0.20 AU).
While in the group receiving 1×106 hESC-CM there was no
difference in cardiac function between mice with small vs
large grafts, in the 3×106 hESC-CM group the mice with small
grafts had a significantly better cardiac function than themicewith large grafts 2 days after MI and at all later time points
(Fig. 4). In addition, infarct size at day 2 after coronary artery
ligation was larger in the group with large grafts (42.1±
3.8 mg; 45.9±4.0% of the LVmass) than in the groupwith small
grafts (31.2±1.9 mg; 39.0±2.7% of the LVmass) (P=0.028) and
the group receiving 1×106 hESC-CM (25.7±0.9 mg; 37.7±1.6%
of the LV mass) (P=0.001). There was a clear correlation
between infarct size at day 2 and EDV, ESV, and EF in
Figure 4 Larger graft size after multiple injections of hESC-CM after myocardial infarction is associated with decreased cardiac
function: Large graft, Np50 for graft size in 3×106 CM group; small graft, Pb50 for graft size in 3×106 CM group. EDV, end diastolic
volume; ESV, end systolic volume; EF, ejection fraction; SV, stroke volume. ⁎ Pb0.05 for large graft vs small graft.
Figure 5 Transplantation of hESC-CM increases vasculariza-
tion in the infarcted heart: Vascular density in infarct (MI),
border zone (BZ), and noninfarcted myocardium (non-MI), 4
weeks after myocardial infarction and injection of 1×106 hESC-
CM or 1×106 hESC-non-CM.
109HESC-CM; vascularity post-MI and graft sizemeasurements after 4 and 12 weeks (4 weeks: r=0.707,
P=0.01 for EDV; r=0.756, P=0.004 for ESV; r=-0.782,
P=0.003 for EF; 12 weeks: r=0.831, P=0.01 for EDV;
r=0.834, P=0.001 for ESV; r=-0.725, P=0.008 for EF).
Hence, in contrast to the difference between the hESC-CM
and hESC-non-CM groups (where function at day 2 was equal),
the reduced improvement in the “large graft” group was
established early after injection of the cells. Since cardiac
function was equal in the mice with small grafts in the 3×106
hESC-CM group and all mice in the 1×106 hESC-CM group, the
optimum relative graft size was approximately 6, which
corresponded to an absolute number of approximately 4000
cells (based on counting nuclei in GFP-fluorescent cells).
In view of the lack of a positive correlation between graft
size and cardiac function, we concluded that active contribu-
tion of donor cardiomyocytes to contraction was unlikely to be
the only mechanism behind the observed functional benefit 4
weeks after MI. For this reason, we analyzed hearts isolated at
this time point for a comparison of multiple parameters that
could be affectedby paracrine action of the transplanted cells:
infarct size, vascularization, and fibrosis and hypertrophy in
areas in the distant noninfarcted myocardium. Infarct circum-
ference was 51.5±6.2 and 61.5±6.0% in the hESC-CM and
hESC-non-CM groups, respectively (P=0.302); infarct volume
averaged 9.8±0.8 mm3 vs 10.8±1.7 mm3 (P=0.519). Vascular
density was significantly increased in the border zone of hearts
injected with hESC-CM compared to hESC-non-CM (Fig. 5 and
Supplementary Fig. 3), and the same trendwas observed in the
infarct area. Fibrosis and hypertrophy were not significantly
decreased in the hESC-CM group (fibrotic score 2.02±0.18 vs
2.28±0.30, P=0.560, and cell size 376±22 vs 442±35,
P=0.197, in the hESC-CM and hESC-non-CM groups, respec-
tively). Thus, while infarct size and remodeling tended to beattenuated in mouse hearts following injection of hESC-CM,
stimulation of vascularization appeared to be a major
contributing factor that may underlie the cardiac functional
improvement 4 weeks after MI.
In order to explain the higher vascular density in the
border zone of hearts containing hESC-CMs versus other hESC
derivatives, we investigated whether the two populations
expressed different levels of two candidate angiogeneic
factors, vascular endothelial growth factor (VEGF) and
transforming growth factor β (TGFβ). Both factors were
expressed at similar levels by qPCR and Western blotting
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dization and immunohistochemistry for VEGF and TGFβ
respectively at 3 days, 4 weeks, and 12 weeks showed
significant expression but no differences between samples
(data not shown). This suggested that either other (co)
angiogenic factors (like FGF or PDGF) are involved or that
differences are not detectable at this level. However, several
other cell types have been described as having similar,
variable effects on local angiogenesis in the heart after
transplantation (Gandia et al., 2008; Cai et al., 2009). The
exact mechanism of this paracrine effect is not known and is
the subject of ongoing study.
Discussion
In this longitudinal follow-up of 12 weeks using serial high-
resolution magnetic resonance imaging, we found that both
hESC-CM and hESC-non-CM provide long-term functional
improvement compared to vehicle or no injection, even
though only cardiomyocytes formed persistent grafts.
Increasing numbers of hESC-CM for transplantation resulted
in no functional benefit and, in fact, smaller grafts were
associated with the best functional outcome. In addition, we
confirmed indications of a paracrine contribution of the
transplanted hESC-CM by demonstrating increased vascular-
ization in the infarcted heart associated specifically with
transplantation of these cells.
In agreement with previous results from transplantation
of hESC-derived cells in uninjured hearts (van Laake et al.,
2007), cardiomyocytes constituted the major proportion of
the grafts. As demonstrated previously (van Laake et al.,
2007) and in view of the low number of Ki-67-positive hESC-
derived cells, this resulted from preferential survival of
cardiomyocytes and loss of noncardiac cells.
Increasing the dose of hESC-CM donor cells 3-fold
translated into manifestly increased graft size. However,
cardiac function did not reflect this enhancement. This is
consistent when cross-comparing data from the literature,
although such an evaluation is obviously less reliable than the
direct comparison we made in our study. Nevertheless, it is
remarkable that Laflamme et al. using rats found an almost
equal improvement (fractional shortening (FS) 4 weeks post-
MI approximately 28% compared to 13–20% in the control
groups; baseline FS approximately 25%) as Caspi et al. (FS 4
weeks post-MI approximately 25% compared to 15% in the
control group; baseline FS 20%) while the models were quite
similar (both performed coronary artery ligation in immuno-
deficient and/or immunosuppressed rats followed by cell
injection 4 (Laflamme et al.) or 7–10 days (Caspi et al.)
later). Exceptionally, the first group transplanted 10 million
cells and the second only 1.5 million (Laflamme et al., 2007;
Caspi et al., 2007).
Independent of the presence of grafts or graft size, both
of the hESC-derived cell preparations used in the present
study significantly improved cardiac function from early time
points onward and this positive effect persisted for at least
12 weeks. Importantly, survival of the mice was also greater
in the cell-injected groups, which suggests that the reported
differences may even underestimate the beneficial conse-
quences of cell transplantation. The absence of a require-
ment for actual cell grafting to mediate functional
improvement is corroborated by other investigations (e.g.,(Muller-Ehmsen et al., 2006)) and points to involvement of
paracrine actions from the donor cells, as described for
mouse ESCs (Ebelt et al., 2006). Increased vascularity may be
sufficient to explain the temporary functional improvement
in mice treated with hESC-CM, as shown previously in a
mouse model of impaired and rescued neoangiogenesis (van
Laake et al., 2006). Additional growth factors and cytokines
may be involved as implied by the consistent trend toward
attenuated remodeling and smaller histological infarct size
in the functionally privileged hESC-CM group 4 weeks post-
MI. Finally, active contribution of cardiomyocytes to con-
traction at this time point could support cardiac perfor-
mance, although this is unlikely to be a very important factor
since there was no extra improvement from larger grafts.
Our unexpected observation that large grafts after 3
injections of 1×106 hESC-CM in the acutely infarcted heart
were associated with reduced cardiac function seemed to
depend at least in part on a larger infarct size 2 days after
the procedure. While injection of liquid substances itself did
not markedly damage the heart, the presence of multiple
large clusters of donor cells may reduce their positive effects
for several reasons. Large dense grafts, especially when
present in the border zone, may block blood supply to the
infarct and border-zone area early after MI. The large grafts
may cause more disruption of the border-zone cardiomyo-
cytes, enhancing disorganization (isotropy) (Wu et al., 2007).
Clusters of cells may also secrete more extracellular matrix,
augmenting the fibrotic gap between donor and host cells
and isolating the graft. Following the “dying stem cell
hypothesis” (Thum et al., 2005) one may reason that in
smaller grafts, more cells have died and secreted favorable
paracrine factors. This may then be a cardiomyocyte-related
effect, considering the functional advantage at 4 weeks of
the hESC-CM group. However, in that case mice receiving
3×106 cells should do better than those receiving 1×106
cells. Finally, we ruled out the possibility that injection was
more successful in coincidentally larger infarcts, by compar-
ing the “likelihood of successful cell retention” (considering
immediate washout of the cells after injection) that was
noted by the surgeon during the procedure, and was identical
in the groups with small and large graft size (Supplementary
Table 1).
Since graft size was not the limiting factor in our cell
transplantation protocol, the lack of a long-term cardiomyo-
cyte-specific advantage might be explained by other short-
comings of the donor cells in this system. We and others
showed that the hESC-CM grafts were largely isolated from
the host myocardium by a layer of fibrotic tissue (Laflamme
et al., 2007; van Laake et al., 2007; Dai et al., 2007) which
prevents the formation of an electrophysiological syncytium.
Our staining for desmoplakin, which showed formation of
desmosomes between human cells but only rarely between
human and mouse, corroborated this. The question remains,
whether junction formation is a possibility at all when human
cardiomyocytes, designed to beat 60 to 100 times per
minute, reside in a rodent heart with frequencies of 300–
600 beats per minute. If human cells were in fact successfully
paced at the rodent's heart rate, this might also account for
loss of function as prolonged periods of tachycardia may
induce cardiac dysfunction. Experiments in larger animals
such as pigs or primates (preferably with ESCs of the same
species (Thomson et al., 1995)) are needed to resolve the
111HESC-CM; vascularity post-MI and graft sizeissue. Grafts may also provide passive support only which
could be sufficient to prevent dilatation and retain cardiac
function temporarily, but is inadequate for sustained
improvement. Similarly, if paracrine mechanisms were the
only modus of action for hESC-CM, these may provide just a
transient protection.
In conclusion, our results show that hESC-CM increase
myocardial vascularization and improve heart function in an
immunodeficient mouse model of MI but lose their functional
advantage over differentiated hESC-non-CM in the long term.
Since increased graft size did not further enhance cardiac
function, the focus of future studies should be on advanced
delivery strategies and unraveling the mechanisms of action
rather than increasing graft size. Development of cell
therapies directed at ameliorating acute ischemic damage
after myocardial infarction could best be directed at
identifying cell types that induce optimal neovascularization
of the border zone.
Methods
Cell culture, differentiation, and dissociation
Cardiomyocyte differentiation of hES3-GFP cells (Costa et
al., 2005) was induced by coculture with END2 cells (Passier
et al., 2005). Large numbers of beating areas were obtained
within 12 days that consist of approximately 25% cardiomyo-
cytes and 75% endodermal or other mesodermal derivates
(Passier et al., 2005). For control experiments hES3-GFP cells
were differentiated on gelatin for 12 days, forming less than
5% α-actinin-positive cells (hESC-non-CM differentiated
control cells). Beating areas, dissected from the hESC-END2
cocultures, or clusters of non-CM control cells, from the
gelatin plates, were dissociated with collagenase (Passier et
al., 2005). Cells were taken up in 15 μl of fresh culture
medium (DMEM + 20% FCS) and used for transplantation.
Animals and surgical procedures
The investigation involving experimental animals conforms
to the Guide for the Care and Use of Laboratory Animals (NIH,
1996) and was approved by the Institute Animal Care
Committee. MI was induced in male NOD-SCID mice (Charles
River) of 11–12 weeks of age (n=13 to 23 per group; total
n=84) by ligation of the LAD under isoflurane anesthesia,
as described previously (van Laake et al., 2007). Directly
afterward, cells or culture media were injected in the
infarcted myocardium through a 29G needle. For experi-
ments with 3×106 cells, one injection was in the infarct and
two were in the border zone. The surgeon was blinded for the
cell type injected. After 4 or 12 weeks, animals were
euthanized and the hearts were fixed and processed for
cryosections as described (van Laake et al., 2007). Lungs,
liver, kidneys, spleen, and brain were also examined for the
presence of tumors.
MRI analysis of cardiac function
Two days, 4 weeks, and 12 weeks post-MI (n=13 to 15 per
group; total n=70), magnetic resonance images were
acquired on a 9.4 T scanner (Bruker, Germany) as described(van Laake et al., 2007). Analysis was performed with Q-mass
software (Medis, the Netherlands) by two blinded
investigators.
Histological analysis
Hearts were cut into 6-μm cryosections (n=6 to 8 per group),
which were stained as described using the following
antibodies: α-actinin (1:800) (mouse, Sigma), troma-1
(1:500) (rat, Developmental Studies Hybridoma Bank),
human CD31 (which does not recognize mouse ECs) (1:300)
(mouse, DAKO), MLC2A (1:100) (mouse, Synaptic Systems),
MLC2V (1:50) (mouse, Synaptic Systems), Ki-67 (1:100)
(rabbit, Abcam), smooth muscle actin (1:100) (rabbit,
Abcam), and desmoplakin (undiluted) (mouse, Progen
Biotechnik). Isotype controls (DAKO) were performed for
each class of antibody used.
Cardiomyocyte size was measured in noninfarcted regions
(septum and RV) using a rabbit-anti laminin antibody (Sigma,
1:100) to define cell borders. In five sections per heart, 10
cross-sectional areas at nuclear level per preset region were
imaged with 400×magnification and measured using Image J
software.
For quantification of vessel density, sections were stained
as described using a rat anti-mouse CD31 antibody (which, in
contrast to the CD31 antibody used for characterization of
the grafted cells, stains mouse ECs), (Clone MEC13.3,
dilution 1:50, BD Biosciences) (van Laake et al., 2006).
Vessel density was averaged from 60 high-power fields per
heart divided over 6 sections at standardized locations along
the long axis of the infarct area using an Olympus-BH2
microscope with AnalySIS software.
Infarct size was measured after AZAN-staining as
described (van Laake et al., 2006) with minor modification
(postfixation with 4% paraformaldehyde, rehydration
through xylene and ethanol). Five sections per heart were
measured with AnalySIS; the longitudinal dimension of the
infarct as measured during cryo-sectioning was used to
reconstruct the absolute infarct volume.
Fibrosis in the noninfarcted area was visualized by Picro-
Sirius red staining (van Veen et al., 2005). The amount of
fibrosis was quantified by measurements in three preset
regions of the noninfarcted area (interventricular septum
and right ventricle). The sections were imaged with a 20×
objective; the images were classified semiquantitatively into
five different groups by two blinded investigators.
Microscopical analysis of GFP-epifluorescence and
immunofluorescent staining
A Leica MZ 16FA / DFC480 fluorescence microscope was used
to image whole hearts. Graft size was categorized semi-
quantitatively into 10 groups by a blinded investigator.
Quantitative graft size was determined by counting GFP-
fluorescent cells in cryo-sections as described previously
(van Laake et al., 2007).
Confocal scanning (with sequential scanning for GFP with
excitation laser 488 nm, Alexa 405 with 405 nm, Cy3 with
532 nm and Topro-3 with 633 nm, respectively) was
performed on a Leica TCS SPE confocal with a DMI4000B
microscope using LAS-AF software.
112 L.W. van Laake et al.Statistical analysis
Statistical significance was evaluated with SPSS v11.5 for
Windows using ANOVA (with Bonferroni correction for multi-
ple-group comparisons) or the Mann-Whitney U test, as
applicable. Survival was analyzed with the Kaplan-Meier
test. Correlations were tested with Pearson's correlation
coefficient. Results are expressed as mean±SEM. A value of
Pb0.05 was considered statistically significant.
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